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Abstract
Lymphangiogenesis is the process that leads to the formation of lymphatic vessels
from pre-existing vessels. Vascular endothelial growth factor C (VEGF-C), the ma-
jor lymphangiogenic growth factor, is produced as an inactive precursor and needs
to be proteolytically processed into a mature form in order to activate its receptors
VEGFR-3 and VEGFR-2. A deficiency of VEGF-C during embryonic lymphan-
giogenesis results in embryonic lethality due to the lack of lymphatic vasculature.
Hennekam lymphangiectasia-lymphedema syndrome (OMIM 235510) is in a subset
of patients associated with mutations in the collagen- and calcium-binding EGF
domains 1 (CCBE1 ) gene. CCBE1 and VEGF-C act at the same stage during em-
bryonic lymphangiogenesis and their deficiency results in similar lymphatic defects.
The mechanism behind the lymphatic phenotype caused by CCBE1 mutations is un-
known. The aim of this study was to investigate the potential link between VEGF-C
and CCBE1 that could contribute to the lymphatic phenotype.
In this study, 293T cells were used to observe the e↵ect of CCBE1 on VEGF-C pro-
cessing. The co-transfection of constructs coding for CCBE1 and VEGF-C showed
processing of the inactive pro-VEGF-C into the active, mature form. However, this
processing was e cient only in 293T cells. When CCBE1 from 293T supernatant
was purified, A disintegrin and metalloproteinase with thrombospondin type 1 mo-
tif 3 (ADAMTS3) co-purified with CCBE1. The levels of pro-VEGF-C and active
VEGF-C were monitored by immunoblotting or immunoprecipitating metabolically
labeled supernatant with specific antibodies or receptors followed by autoradiogra-
phy. The activity of the processed VEGF-C was verified by proliferation of Ba/F3
cells stably expressing VEGFR-3/EpoR or VEGFR-2/EpoR chimeras. Furthermore,
a VEGFR-3 phosphorylation assay was performed in PAE (Porcine Aortic Endothe-
lial) cells to study details of the CCBE1-mediated regulation of VEGF-C.
We found that CCBE1 increases the proteolytic processing of pro-VEGF-C, thereby
resulting in increased activity of VEGF-C. CCBE1 itself has no e↵ect on VEGF-C
activity but regulates VEGF-C by modulating the activity of the ADAMTS3 pro-
tease. We also found that both pro- and mature- VEGF-C can bind to VEGFR-3
but only mature form is able to induce VEGFR-3-mediated signaling. In addi-
tion to cleaving VEGF-C, ADAMTS3 was found to directly or indirectly mediate
CCBE1 cleavage. The N-terminal amino acid sequence of the ADAMTS3-processed
VEGF-C confirmed that ADAMTS3 is the protease responsible for the activation of
VEGF-C by 293 cells. Hence, we have identified a mechanism that regulates VEGF-
C activity. This mechanism suggests the possible use of CCBE1 as a therapeutic
means to treat diseases that involve the lymphatic system.
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1 Introduction
1.1 The vascular system
The primary mode of gas and nutrient transport in primitive animals is di↵usion.
In vertebrates, the vascular system is required for the transport of nutrients, gases,
cells, hormones, metabolic waste products and fluids throughout the body. The
mammalian vascular system includes vessels carrying blood - the circulatory system
- and vessels carrying lymph - the lymphatic vascular system.
The circulatory system comprises a regular and closed network of arteries, veins and
capillaries. Arteries and veins mainly carry the blood, whereas in the capillaries, the
exchange of matter between blood and tissues takes place (Pugsley and Tabrizchi,
2000).
In contrast, the lymphatic vascular system is an open network of lymphatic cap-
illaries, collecting vessels, the thoracic duct and interspersed lymph nodes (Jussila
and Alitalo, 2002).
1.1.1 The structure of the lymphatic system
Lymph originates in the thin-walled lymphatic capillaries by draining the interstitial
spaces. It flows through the collecting vessels and finally enters the subclavian vein
to re-join the blood circulation. The vascular tissues of the human body are well
equipped with lymphatic capillaries (Schmid-Scho¨nbein, 1990), but avascular tissues
like the cornea and cartilage together with a few vascular tissues like the brain
and bone marrow lack lymphatic vessels (Oliver and Detmar, 2002). Lymphatic
capillaries are composed of a single layer of overlapping lymphatic endothelial cells
(LECs), which are attached to the adjacent extracellular matrix via filaments, which
are involved in the regulation of fluid entry into the lumen and which are operated
by interstitial pressure (Leak and Burke, 1966, 1968). The lumen of lymphatic
capillaries is larger compared to the lumen of blood capillaries. The lymph flow in the
collecting lymphatic vessels is maintained by contractions from the smooth muscle
cells (SMCs) surrounding the lymphatic vessel, but normal physiological processes
like respiration and skeletal muscle movement make important contributions to the
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lymph propulsion. Valves in the lymphatic vessels prevent the back-flow of lymph
(Alitalo et al., 2005).
Figure 1: The structure of lymphatic vessels. Blood capillaries feature a con-
tinuous basement membrane and pericytes but lymphatic capillaries lack both. The
lumina of lymphatic capillaries are larger than those of blood capillaries. This
facilitates fluid and macromolecule entry in response to high interstitial pressure.
Lymphatic collecting vessels contain a basement membrane, pericytes, smooth mus-
cle cells and luminal valves. Smooth muscle cells propel the lymph and the valves
prevent the backflow of the lymph. Modified from Norrme´n et al., 2011.
Lymphatic vessels have accessory organs; the lymphoid organs. There are three
types of lymphoid organs. Primary lymphoid organs are the thymus and the bone
marrow and function in the formation and maturation of lymphocytes. Secondary
lymphoid organs are spleen, lymph nodes, appendix, tonsils and payer’s patches; and
they have critical roles in modulating the immune response (Margaris and Black,
2012). Tertiary lymphoid organs are organized structures formed from aggregates
of B and T-cells in response to chronic inflammation and are structurally similar
to the lymph nodes (Neyt et al., 2012). The lymph nodes are complex organs in
which macrophages, lymphocytes and dendritic cells interact with each other and
encounter invading pathogens before they enter the blood circulation (Ohtani and
Ohtani, 2008; Swartz, 2001).
1.1.2 The function of the lymphatic system
One of the important functions of the lymphatic system is to maintain tissue fluid
homeostasis. The lymphatic capillaries take up surplus interstitial fluid, which has
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leaked from the blood vessels due to the blood pressure. This fluid is then trans-
ported back into the blood vascular system (Casley-Smith, 1985).
Beside its role in tissue fluid homeostasis, the lymphatic system has well-established
roles in the immune defense where T cells and B cells encounter antigen in coordi-
nation with antigen presenting cells at the lymph node; thereafter transmitting the
immune encountered cells to the systemic circulation (Kesler et al., 2013; Mackay
et al., 1990). One example of innate immune defense orchestrated by the lymphatic
system occurs through Toll-like receptor (TLR-4) signaling. LECs express high lev-
els of TLR-4, which can be activated by lipopolysacharides (LPS). This results in the
generation of chemokines that recruit macrophages, which induce lymphangiogene-
sis by secreting the lymphatic specific growth factors VEGF-C and -D (Kang et al.,
2009). Furthermore, emerging evidence of the lymphatic system’s role in inflamma-
tory responses by modulating lymphangiogenic factors VEGF-C and VEGFR-3 has
encouraged researchers to develop therapeutic strategies targeting the lymphatics
to control chronic inflammations (Huggenberger et al., 2010).
Besides the role in fluid homeostasis and immune defense, the lymphatic system
plays a third, important function in the digestive tract. Intestinal absorption of
dietary lipids in the form of chylomicrons is the role of specialized lymphatic vessels
in the small intestine called lacteals (Choi et al., 2012).
1.2 Lymphangiogenesis
1.2.1 Development of the lymphatic system
The development of the lymphatic system in the mouse starts at E10.5, much later
than the development of the cardiovascular system, which starts around E6.5-7
(Wigle and Oliver, 1999). Two opposing theories were proposed in the beginning of
the 20th century. The centrifugal sprouting theory by Sabin advocates the formation
of lymphatic vessel from primary lymph sacs, which itself originate from embryonic
veins (Sabin, 1902), whereas the centripetal sprouting theory by McClure and Hunt-
ington proposes lymph sac formation without a blood vascular origin (Huntington
and McClure, 1910). However, results have been published in support of both cen-
trifugal (Dumont et al., 1998; Ha¨gerling et al., 2013; Srinivasan et al., 2007; Wigle
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and Oliver, 1999; Wigle et al., 2002) and centripetal sprouting (Papoutsi et al., 2001;
Schneider et al., 1999). Interestingly, a Xenopus laevis based genetic model suggests
that both centripetal and centrifugal processes can coexist in the development of
the lymphatic vasculature. The mode of development of the lymphatic vasculature
appears to depend on the model organism being studied (Ny et al., 2005).
1.2.2 Lymphatic endothelial cell specification
Transcription factors like Prox1, CoupTFII, Sox18 and FoxC2 play vital roles in the
lymphatic vasculature development; the first three being important in specification
of the lymphatic fate while the latter has a role in the formation of lymphatic valves
(Franc¸ois et al., 2011; Petrova et al., 2004).
Prospero-Related Homeobox Domain 1 (Prox1), a specific marker for LECs, is an
important factor in deciding the identity of LECs and later in the migration of
LECs, but it is not required for the initial budding of endothelial cells from the
anterior cardinal veins. Prox1 null embryos lack lymph sacs and hence have no
lymphatic vasculature (Wigle and Oliver, 1999). They don’t show any significant
expression of lymphatic markers but show expression of BEC-specific markers (Wigle
et al., 2002). This was consistent with the results obtained from two independent
studies overexpressing Prox1 in primary blood vascular endothelial cells. The results
indicated upregulation of various lymphatic specific genes and downregulation of
blood vascular specific genes supporting the notion that Prox1 could reprogram
blood vascular endothelial cells to resemble lymphatic endothelial cells (Hong et al.,
2002; Johnson et al., 2008; Kim et al., 2010).
Sox-18 is required for the di↵erentiation of lymphatic endothelial cells from the
cardinal vein and also induces the expression of Prox1 along with other lymphatic
markers (Franc¸ois et al., 2008). Similarly, conditional deletion of Nr2f2 in mice
during the early stage of lymphatic development restricts lymph sac formation and
is essential during later stage of lymphatic development to maintain LECs iden-
tity. The gene product of Nr2f2, COUP-TFII, exerts its function by regulating
the expression of neuropilin2 (Nrp2), a co-receptor for VEGF-C (Tsai et al., 2010).
Additionally, COUP-TFII forms homodimers resulting in the continuation of the
venous identity, while COUP-TFII heterodimerization with Prox1 appears to be
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involved in the di↵erentiation into the lymphatic direction (Aranguren et al., 2013).
Apart from the importance of transcription factors in deciding the lymphatic fate,
NOTCH1 expression tightly regulates the specification of BECs into LECs through
the suppression of Prox1 and upregulation of blood vasculature-specific VEGFR-2
and Nrp1 (Kang et al., 2010). It has also been shown that inhibition of NOTCH
signaling, both in vivo and in vitro, promotes lymphangiogenesis (Zheng et al.,
2011).
1.2.3 Regulation of the expansion of the lymphatic vascular network
The co-localization of VEGF-C and its receptor VEGFR-3 during the process of
lymphatic development suggested a role of the VEGFR-C/VEGFR-3 signaling axis
in the regulation of the lymphatic vasculature development (Kukk et al., 1996).
Studies of Vegfc -/- embryos highlighted the role of VEGF-C in the budding and
migration of LECs from the anterior cardinal vein. VEGF-C deletion prevents the
migration of LECs thereby resulting in a complete lack of the lymphatic vasculature.
VEGF-C apparently has no role in the specification of the lymphatic fate (Ha¨gerling
et al., 2013; Ka¨rkka¨inen et al., 2004). This was consistent with the role of VEGF-C
in the lymphatic development of zebra fish (Ku¨chler et al., 2006).
The expansion of the lymphatic vascular network is mostly dependent upon VEGF-
C/VEGFR-3 signaling (Ma¨kinen et al., 2001b) and interstitial pressure (Planas-Paz
et al., 2011). The use of VEGF-C traps like soluble VEGFR3/IgG-Fc chimeras in
mouse embryos after E14.5 results in hypoplastic lymphatic vessels (Ma¨kinen et al.,
2001b). Also in adults, VEGF-C seems to be the major stimulant for lymphan-
giogenesis (Ka¨rpanen and Alitalo, 2008). Surgical removal of lymph nodes in the
treatment of malignant tumors has been a common practice, which frequently re-
sults in lymphedema as a side e↵ect. The adenoviral delivery of VEGF-C/VEGF-D
to mice with removed axillary lymph node and lymphatic vessels resulted in a regain
of functional lymphatic vessels, demonstrating one of the therapeutic strategies to
treat lymphedema conditions in adults (Tammela et al., 2007).
Neuropilin-2 (Nrp2), a co-receptor for VEGF-C, is expressed by ECs of veins and
lymphatic vessels. Nrp2 mutant mice show defects in the growth of small lymphatic
vessels and capillaries during development (Yuan et al., 2002). This was later sup-
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Figure 2: The development of lymphatic vessels. COUP-TFII and Sox18,
expressed in the venous endothelial cells, stimulate Prox1 expression and hence
lymphatic fate specification. The separation of LECs from venous endothelial cells
requires SH2 domain containing leukocyte protein of 76kDa (slp76) and spleen ty-
rosine kinase (syk). The di↵erentiating LECs form the primary lymph sacs after
VEGF-C stimulated emigration from their venous origin. Important molecules in-
volved in the later stages of lymphatic development are neuropilin 2 (Nrp2), forkhead
box C2 (Foxc2), podoplanin (Pdpn), angiopoietin 2 (Ang2), ephrin B2 (Efnb2) and
integrin ↵9. Figure modified from Alitalo et al., 2005; Oliver and Srinivasan, 2010
and Tammela and Alitalo, 2010.
ported by an independent experiment where blocking of Nrp2 binding to VEGF-C
prevented sprouting of endothelial cells during the lymphatic development. The
lymphangiogenic activity of Nrp2 is accomplished by its interaction with VEGFR-3
when stimulated by VEGF-C (Xu et al., 2010). The stimulation of human lymphatic
endothelial cells with VEGF-C/VEGF-D leads to the endocytosis of VEGFR-3 and
Nrp2, probably regulating the receptor based signaling process (Ka¨rpanen et al.,
2006).
1.2.4 Remodeling and maturation of lymphatic vessels
Several proteins have been identified that assist in the process of remodeling and
maturation. The forkhead transcription factor Foxc2 is expressed in LECs during
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the development of lymphatic vessels, and mutations in FOXC2 are associated with
lymphedema-distichiasis syndrome in humans. The disease is characterized by lower
limb lymphedema and distichiasis (a double row of eye lashes; Dagenias et al., 2004)
. The study of Foxc2 -/- mice revealed defects in lymphatic vascular patterning
and a role of Foxc2 in keeping the lymphatic capillary network free of pericytes and
SMCs (Petrova et al., 2004). Later, another study described the interaction between
Foxc2 and NFATc1 (Nuclear factor of activated T cells) downstream of VEGFR-3
signaling being responsible for lymphatic vessel maturation; thus supporting the
earlier evidence (Kulkarni et al., 2009).
The role of TGF  (transforming growth factor  ) in lymphatic vascular develop-
ment is not yet clear. One of the functions of TGF  could be to enhance lymphatic
sprouting and lymphatic network formation, resulting in enhanced lymphangiogene-
sis as shown in the skin of mice during development (James et al., 2013). A mutation
in the C-terminal PDZ domain of ephrinB2, the ligand for ephrin type-B receptor
2 tyrosine kinase, results in a failure of lymphatic vessel remodeling and lymphatic
luminal valve formation (Ma¨kinen et al., 2005).
Additionally, the role of Ang/Tie signaling in lymphatic development has been stud-
ied in detail. The endothelial cell specific tyrosine receptors, Tie1 and Tie2 are
expressed by lymphatic endothelial cells (D’Amico et al., 2010; Saharinen et al.,
2005). Tie1 -/- mice show defects in the lymph sac patterning and edema forma-
tion (D’Amico et al., 2010). Ang2 -/- mice show defects in the formation of large
collecting lymphatic vessel and poor association with SMCs; highlighting the role of
Ang2 in maturation of lymphatic vessels during the later stages of embryonic devel-
opment (Gale et al., 2002). Ang1, the ligand for Tie2, can induce lymphangiogenesis
in vivo in adult mice (Tammela et al., 2005), but can also rescue the phenotype from
Ang2 -/- mice (Gale et al., 2002).
The development of the lymphatic system is a complex process with probably many
unidentified players and mechanisms.
1.2.5 Lymphangiogenesis in adults
Lymphatic endothelial cells in adults are normally quiescent. The roles and mecha-
nisms of angiogenesis in adults are well understood but lymphangiogenesis in adults
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is less well understood.
Adult lymphangiogenesis is involved in tumor metastasis, which will be discussed in
the section Tumor lymphangiogenesis.
1.3 Molecular regulation of lymphangiogenesis
The assembly of lymphatic endothelial cells into lymphatic vessels requires a balance
between VEGF-C and VEGFR-3 along with other regulatory factors and processes.
Hence, it is interesting to study regulatory factors, which could play vital roles in
the physiology of lymphangiogenesis.
1.3.1 Vascular endothelial growth factors
The mammalian VEGF gene family consists of 5 members: VEGF (also known as
VEGF-A), VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). The
VEGF family of growth factors comprises the ligands for vascular endothelial growth
factor receptors (VEGFRs). VEGFs are the major molecular players regulating
the processes of angiogenesis and lymphangiogenesis. The signaling between the
growth factors and their receptors is complex and often crosstalk between di↵erent
members of the VEGF family and their receptors occurs (Norrme´n et al., 2011).
The binding of VEGFs to their receptors is guided by the di↵erential a nities of
the VEGFs for di↵erent receptors (Ka¨rpanen and Alitalo, 2008). VEGFs belong
to the VEGF/PDGF (platelet derived growth factor) family of growth factors and
contain the central VEGF homology domain (VHD) characterized by the presence of
eight conserved cysteine residues participating in intra- and inter- molecular disulfide
bonds (Fairbrother et al., 1998).
1.3.2 VEGF
Vascular endothelial growth factor (VEGF) is the major mitogen for endothelial
cells and is involved in both normal, developmental and pathological angiogenesis
(Ferrara et al., 1998; Miquerol et al., 2000). It is the major angiogenic and vas-
culogenic factor (Carmeliet et al., 1996) and regulates endothelial cell proliferation
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and migration (Bernatchez et al., 1999). VEGF can be produced by all the cells of
the body (Ferrara et al., 1992) and hypoxia is the major inducer for VEGF expres-
sion (Liu et al., 1995), regulated via the transcriptional activator HIF-1↵ (Forsythe
et al., 1996). Additionally, the expression of VEGF is stimulated by inflammatory
cytokines, oncogenes and growth factors (Ferrara et al., 2003).
The e↵ect of VEGF on lymphangiogenesis has been controversial. Adenoviral de-
livery of VEGF-A164 to adult mice resulted in formation of giant lymphatic vessels
with reduced function (Nagy et al., 2002) but the mechanism causing this pheno-
type was not described. However, the e↵ect of VEGF on lymphangiogenesis has
been suggested to be indirect. In the mouse model of inflammatory corneal neo-
vascularization, VEGF can recruit macrophages to the inflammatory tissues via
VEGFR-1 and the recruited macrophages could induce lymphangiogenesis by se-
creting VEGF-C (Cursiefen et al., 2004). Similarly, VEGF overexpressing tumor
models in mice showed peri-tumoral lymphangiogenesis and lymph node metastasis,
further reflecting the potential role of VEGF in lymphangiogenesis (Bjo¨rndahl et al.,
2005; Hirakawa et al., 2005).
Figure 3: Growth factors of the VEGF family and their receptors
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1.3.3 VEGF-B
VEGF-B, also known as VEGF related factor (VRF), has two isoforms (VEGF-B167
and VEGF-B186) as a result of alternative splicing (Olofsson et al., 1998). Recent
studies in mice show a potential role of VEGF-B in cardiac conduction (Aase et al.,
2001) and prevention of ischaemic heart disease (Kivela¨ et al., 2014). However, more
studies are needed to understand the role of VEGF-B in order to be able to utilize
it as a therapeutic target.
1.3.4 PlGF
The name PlGF comes from its discovery from human placenta (Maglione et al.,
1991), but it is also expressed in heart, lungs and skeletal muscle (Falco, 2012).
PlGF stimulates endothelial cell growth (Maglione et al., 1993), but its deficiency
has no e↵ect on embryonic angiogenesis (Carmeliet et al., 2001). In contrast to the
embryonic e↵ect, PlGF seems to have a significant angiogenic e↵ect under ischaemic
conditions in heart inflammation (Carmeliet et al., 2001; Luttun et al., 2002), and
it also shows an arteriogenic e↵ects which are mediated by monocytes (Pipp et al.,
2003).
1.3.5 VEGF-C, the major lymphangiogenic factor
VEGF-C (or VEGF-related protein, VRP) was identified in 1996 by two independent
groups (Joukov et al., 1996; Lee, 1996). The 419 amino acid residue protein features
long N- and C-terminal extensions flanking the central VEGF homology domain
(VHD). The C-terminal domain of VEGF-C contains a repetitive cysteine pattern
resembling the Balbiani ring 3 domains protein (BR3P). VEGF-C expression starts
in embryos at E8.5 and reaches its peak at E12.5 during the formation of the primary
lymph sacs after LEC emigration from the embryonic veins (Kukk et al., 1996).
VEGF-C mRNA is expressed in lymph nodes, heart, kidney, muscle, placenta, ovary
and small intestine (Lee, 1996).
Proteolytic processing. VEGF-C is synthesized as a preproprotein, consisting
of an N-terminal signal sequence, an N-terminal propeptide, the VEGF homology
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domain (VHD) and the C-terminal propeptide (Joukov et al., 1996). VEGF-C
undergoes stepwise proteolytic processing (Figure 4) which has a significant e↵ect
on the a nity of VEGF-C towards its two known receptors VEGFR-3 and VEGFR-
2. The mature form (referred to as 21/23 form) exists as homodimer and binds both
receptors (Joukov et al., 1997; Stacker et al., 1999). The mature form contains two
N-glycosylation sites (out of the three N-glycosylation sites in pro-VEGF-C) and
nine cysteine residues (Joukov et al., 1997). The proteolytic processing of VEGF-C
is not completely understood. The limited information about the processing is based
on transfection studies in cell lines. The proprotein convertases furin, PC5 and PC7
cleave VEGF-C at the C-terminus into pro-VEGF-C. This happens probably before
secretion (Siegfried et al., 2003). Similarly, the serine protease plasmin can cleave
VEGF-C at the N-terminus generating a mature form of VEGF-C capable of binding
to both VEGFR-2 and -3 (McColl et al., 2003).
Figure 4: Model of proteolytic processing of VEGF-C. VEGF-C domain struc-
ture starting from the N-terminus: Signal peptide (SP), N-terminal propeptide,
VEGF homology domain (VHD) and C-terminal propeptide. The processing occurs
in a stepwise manner starting from unprocessed (prepro-VEGF-C) via pro-VEGF-
C to the mature VEGF-C, which has angiogenic in addition to lymphangiogenic
activity.
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Biological activity. The role of VEGF-C in lymphangiogenesis is well estab-
lished. The importance of VEGF-C during embryonic lymphangiogenesis has been
discussed in the section Development of the lymphatic system. VEGF-C induces hy-
perplasia of lymphatic vessels in the skin of transgenic mice and the chick chorioal-
lantoic membrane (Jeltsch et al., 1997; Oh et al., 1997; Veikkola et al., 2001). Ho-
mozygous deletion of Vegfc in mice is lethal for the embryos and heterozygous dele-
tion results in lymphatic hypoplasia and lymphedema (Ka¨rkka¨inen et al., 2004).
Mutation of Cys-156 into serine strongly reduces binding of VEGF-C to VEGFR-2
(Joukov et al., 1998). In zebrafish, Vegfc is both angiogenic and vasculogenic during
early vascular development (Ober et al., 2004). In transgenic mice, induced over-
expression of VEGF-C stimulates angiogenesis and lymphangiogenesis in embryos,
but the e↵ect is restricted to the lymphatic vessel in adults (Lohela et al., 2008).
VEGFR-3, the receptor for VEGF-C, is expressed in all endothelial cells during the
early stages of development but becomes limited to the LECs later in development
(Kukk et al., 1996). VEGFR-2, the second receptor for VEGF-C, is expressed in
both LECs and BECs in vitro (Kriehuber et al., 2001) and in agreement with this,
both LECs and BECs grow and migrate in response to VEGF-C (Ma¨kinen et al.,
2001a).
VEGF-C mRNA levels are not regulated by hypoxia (Enholm et al., 1997). However,
VEGF-C protein levels have been shown to be regulated via an internal ribosome
entry site (IRES) under hypoxia (Morfoisse et al., 2014). VEGF-C expression has
also been shown to increase in the presence of pro-inflammatory cytokines (Ristima¨ki
et al., 1998).
1.3.6 VEGF-D, the “other” lymphangiogenic factor
VEGF-D (c-fos induced growth factor, FIGF) is structurally similar to VEGF-C
and is also similarly processed (Orlandini et al., 1996; Stacker et al., 1999). Hu-
man VEGF-D, like VEGF-C, binds to both VEGFR-2 and VEGFR-3 (Achen et al.,
1998), but binding of VEGF-D to VEGFR-2 is absent in mice (Baldwin et al., 2001).
VEGF-D stimulates the migration of capillary endothelial cells (Achen et al., 1998)
and induces lymphangiogenesis and angiogenesis in adult tissues (Byzova et al.,
2002). Unlike VEGF-C, VEGF-D deficient mice have no significant lymphatic phe-
notype (Baldwin et al., 2005). Hence, VEGF-C appears to be the major lymphan-
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giogenic factor and VEGF-D might act as a redundant factor. This has been shown
in the double Vegfc -/- :Vegfd -/- mice whose lymphatic phenotype resembles the
one of the Vegfc -/- mice (Haiko et al., 2008).
1.3.7 Vascular endothelial growth factor receptors (VEGFRs)
VEGFRs belong to the class III receptor tyrosine kinases and consist of seven extra-
cellular immunoglobulin (Ig) homology domains, a single transmembrane domain
and an intracellular tyrosine kinase domain. They are indispensable for vascular
development in general as well as for maintaining the vascular integrity in the adult
(Olsson et al., 2006).
VEGFR-1. VEGFR-1 (Fms-like tyrosine kinase 1, Flt1) is normally expressed
on blood vascular endothelial cells, macrophages, dendritic cells and hematopoietic
stem cells (Shibuya, 2001). VEGFR-1 has a strong a nity for VEGF (de Vries
et al., 1992), PlGF (Park, 1994) and VEGF-B (Olofsson et al., 1998). VEGFR-1
can also crosstalk with VEGFR-2 by forming heterodimers (Autiero et al., 2003).
VEGFR-2. VEGFR-2 (fetal liver kinase 1, Flk1 in mice and KDR in humans)
is the major angiogenic receptor and is involved in survival, growth, sprouting and
migration of endothelial cells (Gille et al., 2001). Mice deficient in Vegfr2 show
embryonic lethality as a result of disrupted vasculogenesis and hematopoiesis (Sha-
laby et al., 1995). Compared to VEGFR-1, VEGFR-2 has a stronger tyrosine ki-
nase activity when stimulated with VEGF (Waltenberger et al., 1994). VEGFR-2
has a nities for VEGF-A, VEGF-E, pro/mature VEGF-C and mature VEGF-D
(Shibuya and Claesson-Welsh, 2006).
VEGFR-3. During biosynthesis, VEGFR-3 (Flt4) becomes proteolytically cleaved
within its fifth Ig homology domain (Pajusola et al., 1994). However, mutations pre-
venting the processing have no e↵ect on its kinase activity (Tvorogov et al., 2010).
VEGFR-3 homodimerizes after binding its ligands VEGF-C or VEGF-D and it also
can heterodimerize with VEGFR-2 with consequential di↵erences for its signaling
capacity (Dixelius et al., 2003). In the early stage of development (before the forma-
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tion of lymphatic vessels), VEGFR-3 is expressed on blood vessels and has a vital role
in the early stages of cardiovascular development (Dumont et al., 1998). Once the
lymphatic vessels arise, VEGFR-3 expression becomes restricted to the lymphatic
compartment (Kaipainen et al., 1995) and has a role in the survival and maintenance
of lymphatic vessels (Ka¨rkka¨inen et al., 2004). However, VEGFR-3 expression can
be upregulated in blood vessels during pathological conditions (Paavonen et al.,
2000; Partanen et al., 1999).
1.4 Lymphangiogenesis in disease
The function of the lymphatic system is compromised in many diseases. Disorders
can be characterized by either lymphatic insu ciency or pathological lymphatic
growth like in tumor lymphangiogenesis or inflammation.
1.4.1 Lymphedema
Lymphedema is the condition of lymphatic insu ciency due to aberrant, dysfunc-
tional or absent lymphatic vessels, obstruction of the normal flow of lymph or in-
creased capillary filtration leading to accumulation of interstitial fluid, thereby in-
creasing the interstitial pressure. It visually manifests as swelling of the face, arms,
legs or the abdominal wall. Lymphedema can be classified into primary lymphedema
(hereditary) or secondary (acquired) lymphedema (Norrme´n et al., 2011).
Primary lymphedemas are rare diseases. Table 1 summarizes various types of pri-
mary lymphedema with features and molecular mechanisms.
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Milroy disease (OMIM 153100), a type of congenital lymphedema, has been found to
be associated with missense mutations in the FLT4 gene (Connell et al., 2009; Evans
et al., 2003; Ferrell et al., 1998; Ka¨rkka¨inen et al., 2000) and results in hypoplastic
or aplastic lymphatic capillary networks (Mellor et al., 2010). In vitro and in vivo
studies have shown that mutations in the tyrosine kinase domain of VEGFR-3 can
compromise VEGFR-3 signaling (Ka¨rkka¨inen et al., 2000, 2001). Recently, a frame-
shift mutation in VEGFC has also been identified with a phenotype similar to Milroy
disease and the mutant protein had no lymphangiogenic activity in the zebrafish
model (Gordon et al., 2013).
Mutations in the transcription factor FOXC2 can cause Lymphedema-distichiasis
syndrome (Finegold et al., 2001), and SOX18 can cause Hypotrichosis-lymphedema-
telangiectasia syndrome (Irrthum et al., 2003). Hennekam lymphangiectasia-lymphedema
syndrome is in a subset of patients associated with point mutations in the CCBE1
gene (Alders et al., 2009).
Secondary lymphedema represents the major fraction of lymphedema incidence
worldwide and can result from radiation, surgery or infection, causing a defective
lymphatic vasculature (Warren et al., 2007). Filariasis, the infection caused by
nematodes like Wuchereria bancrofti and Brugia malayi (Dreyer et al., 2000) af-
fects millions of lives in tropical areas and it can result in secondary lymphedema.
Lymphatic filariasis features blockage of normal lymph flow, which is caused by
the accumulation of adult worms in the lymphatic vasculature (Pfarr, 2009). An-
other common form of secondary lymphedema can result as a complication from
postmastectomy radiotherapy (PMRT) and/or lymph node removal (Hinrichs et al.,
2004).
There are not many options for treating lymphedema except physiotherapy or com-
pression treatment (Warren et al., 2007). However, the discoveries of the genetic
causes of lymphedema have paved the way for the development of therapeutic strate-
gies.
1.4.2 Tumor lymphangiogenesis and metastasis
Metastasis is the complex process by which tumor cells spread from the primary tu-
mor to a distant, secondary site with often fatal consequences for the patient (Fidler,
16
2003). Tumor metastasis can occur via two routes: through the blood vasculature
(Zetter, 1998) or via the lymphatic vasculature, followed by later dissemination of
tumor cells into the blood vasculature (Alitalo et al., 2005). The role of the blood
vasculature in tumor progression has been well established, but the contribution of
the lymphatic vasculature is poorly understood (Skobe et al., 2001). The advent
of lymphatic-specific markers has played a significant role in studying lymphangio-
genesis in cancer progression with large numbers of articles claiming its importance.
Clinical studies of cancer have often identified lymph node metastasis as a common
event in the carcinoma development of breast, prostate, and colon as well as in
melanoma (Kawada and Taketo, 2011). Lymph node metastasis has also been used
as a clinical prognostic marker for tumor aggressiveness (Nathanson, 2003).
Figure 5: Summary of lymphatic metastasis. The tumor secretes VEGF-C and
VEGF-D. Tumor cells express inflammatory cytokine receptors like CCR7 to stimu-
late lymphangiogenesis, lymphatic vessel hyperplasia and tumor cell dissemination
into local lymphatic vessels and lymph nodes. VEGF, Ang2 and macrophages con-
tribute to the metastatic process. The disseminated tumor cells can translocate
further to distant lymph nodes and even drain back into blood vessels, from where
they can colonize still other cites.
In vivo studies have shown the presence of lymphatic vessels at the tumor periph-
ery, where they play a role in the passaging of tumor cells (Deutsch et al., 1992;
Leu et al., 2000). In contrast, there is an absence of functional lymphatics within
solid tumors because of the physical conditions (e.g. pressure) within tumors (Jain
and Fenton, 2002; Padera et al., 2002). However, there have been a few studies
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that suggested the presence of proliferative intra-tumoral lymphatic vessels in some
human cancers (Beasley et al., 2002; Dadras et al., 2003; Maula et al., 2003), but
it is commonly believed that intra-tumoral lymphatic vessels are not a prerequisite
for metastasis (Wong et al., 2005). The lymphatic vessels exceed blood vessels in
terms of permeability and hence lymphatic vessels are more likely to be penetrated
by tumor cells (Alitalo et al., 2005).
VEGF-C is produced by many solid tumors and its expression correlates with the
metastatic potential of the tumor (Mandriota et al., 2001; Mattila et al., 2002;
Skobe et al., 2001). Furthermore, clinical studies in melanoma patients have shown
poor prognosis for patients with high expression of VEGF-C mRNA (Goydos and
Gorski, 2003). The significant upregulation of VEGF-C in tumors accompanies the
development of resistance to anti-VEGF therapy (Li et al., 2014). Recently, studies
in patients with mantle cell lymphoma and in a comparable mouse model elucidated
the expression of VEGF-C by tumor associated macrophages as a major stimulator
of lymphangiogenesis (Song et al., 2013). Contrary to VEGF-C, the influence of
its homolog VEGF-D on metastasis remains controversial. Both upregulation of
VEGF-D (Stacker et al., 2001; Von Marschall et al., 2005) and downregulation (O-
charoenrat et al., 2001) have been observed in di↵erent tumors.
Lymphatic endothelial cells produce the chemokines CCL21 (Gunn et al., 1998)
and CXCL12 (Mu¨ller et al., 2001). These chemokines are ligands for the recep-
tors CCR7 and CXCR4, which are broadly expressed by tumor cells. Inhibition of
CXCL12/CCL21 interactions resulted in a significant reduction in lymph node and
lung metastasis (Mu¨ller et al., 2001).
The establishment of the role of VEGF-C/VEGF-D and VEGFR-3 signaling in
tumor progression transformed this axis into one of the major targets for thera-
peutic intervention. Several studies using neutralizing antibodies against VEGF-D
(Achen et al., 2000) and VEGFR-3 (Chaudary et al., 2011; Roberts et al., 2006;
Shimizu et al., 2004), siRNA targeted against VEGF-C (Chen et al., 2005) and sol-
uble VEGFR-3 fusion proteins (Lin et al., 2005) have shown significant e↵ects on
the inhibition of tumor lymphangiogenesis and hence on the metastasis.
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1.5 Targeting lymphangiogenesis for therapy
Therapeutic strategies targeting the lymphatic system can be either pro-lymphang-
iogenic (for the treatment of lymphatic insu ciency) or anti-lymphangiogenic (to
blunt a disease-promoting lymphangiogenic response).
1.5.1 Pro-lymphangiogenic therapy
Stimulating lymphatic growth to treat lymphatic insu ciency diseases like primary
lymphedema would treat the underlying cause of the disease and hence will be
complementary to the traditional symptomatic treatment strategies. An adeno-viral
vector encoding VEGF-C significantly stimulated lymphangiogenesis when injected
into adult mice (Enholm et al., 2001). Similarly, VEGF-C gene therapy in the
Chy-mouse model of primary lymphedema enhanced the expression of VEGFR-
3, thereby leading to the growth of functional lymphatic vessels (Ka¨rkka¨inen et al.,
2001). The delivery of VEGF-C and Ang2 using a hydrogel HAMC (hyaluronan and
methylcellulose) delivery system into the nodal removal site was able to reconstitute
lymphatic function and significantly reduce edema (Baker et al., 2010).
1.5.2 Anti-lymphangiogenic therapy
In metastasis, tumor cells can either travel via the lymphatic or the blood vascu-
lature. Lymphatic metastasis is common in many cancer types. Several preclinical
therapies have been devised based on anti-lymphangiogenesis like siRNA against
VEGF-C (Chen et al., 2005), monoclonal antibodies against VEGF-C (e.g. VGX-
100; Falchook et al., 2013), VEGFR31-Ig (Zhang et al., 2010), monoclonal antibodies
against (e.g.VD1, Achen et al., 2000) and monoclonal antibodies against VEGFR-3
(Roberts et al., 2006). The successful development of Avastin as anti-angiogenic
drug has spurred the search for an anti-lymphangiogenic therapy to treat tumor
metastasis. One advantage of anti-lymphangiogenic therapy could be the absence of
on-target side e↵ects due to the relatively low lymphangiogenic activity in adults.
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1.6 CCBE1 as a novel regulator of lymphangiogenesis
Collagen and calcium binding EGF domains 1 (CCBE1) is a secreted protein with
406 AA residues (in humans) containing N-terminal EGF-like repeats and a C-
terminal domain with two collagen-like repeats (Hogan et al., 2009). Hennekam
lymphangiectasia-lymphedema syndrome (OMIM 235510), short Hennekam syn-
drome or HS, is a rare autosomal recessive disorder characterized by lymphedema,
lymphangiectasia and mental retardation (Van Balkom et al., 2002). Mutations in
CCBE1 are associated with the Hennekam syndrome in a subset of patients, but
the molecular mechanism behind the lymphatic vasculature abnormalities remained
unclear (Alders et al., 2009). Mutations found in CCBE1 mostly occur in the N-
terminal EGF-like repeats which contain conserved cysteine residues and are thought
to be crucial for the integrity of the protein (Alders et al., 2009).
Figure 6: Schematic view of the structure of CCBE1. Mutations in CCBE1
as seen in Hennekam Syndrome. SP : signal peptide, GlcNAc: potential N-linked
glycosylation site, EGF CA: EGF-like calcium binding domain. Domain information
retrieved from Uniprot (http://www.uniprot.org/uniprot/Q6UXH8).
CCBE1 is probably not produced by endothelial cells but it is essential for embry-
onic lymphangiogenesis based on studies in zebrafish and mice (Bos et al., 2011;
Hogan et al., 2009). Ccbe1 -/- mice have fewer di↵erentiated LECs and the primary
lymph sacs do not form. This suggests a possible role of CCBE1 in LEC budding,
sprouting, migration and lymph sac assembly (Bos et al., 2011). Although VEGF-C
and CCBE1 display similar phenotypic features during the development of the lym-
phatic vasculature, the cause for this similarity remained largely unknown (Hogan
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et al., 2009).
CCBE1 has also been shown to act like a tumor suppressor in ovarian cancer, as its
loss promoted cellular migration and survival (Barton et al., 2009). Additionally,
evidence suggesting CCBE1 as a marker of cardiac precursors during early stages of
mouse development implies a possible function of CCBE1 during heart morphogen-
esis (Facucho-Oliveira et al., 2011).
1.7 A disintegrin and metalloproteinase with thrombospondin
type I motif 3 (ADAMTS3)
A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) pro-
teases are structurally similar to the ADAMs proteases. ADAMs are typically trans-
membrane proteases, whereas ADAMTSs are typically secreted proteases (Kuno
et al., 1997). The schematic structure of human ADAMTS3 is shown in Figure 7.
Figure 7: Schematic view of the structure of ADAMTS3. TSP-1: Throm-
bospondin 1; PLAC: Protease and lacunin. Domain information retrieved from
Uniprot (http://www.uniprot.org/uniprot/O15072).
The ADAMTS family consist of 19 members (Stanton et al., 2011). ADAMTSs
have at least one furin recognition site. Upon cleavage at this site, the ADAMTS
proteases become activated (Brocker et al., 2009). Moreover, some results suggest
further processing of ADAMTSs in the C-terminal region, which might be important
for the regulation of ADAMTSs activity and availability in the extracellular matrix
(Rodr´lguez-Manzaneque et al., 2000). ADAMTSs are classified into seven major
subfamilies (Llamazares et al., 2003). The subfamilies are shown in Table 2.
The group consisting of ADAMTS-2, -3 and -14 is also referred to as the procollagen-
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Table 2: The subfamilies of human ADAMTS proteins. Modified from Ll-
mazares et al., 2003 and Porter et al., 2005; ⇤: not assigned.
Subfamilies of
ADAMTS
ADAMTS Function
Aggrecanases
ADAMTS-1
ADAMTS-4
ADAMTS-5 Cleave the major cartilage proteoglycan aggrecan
ADAMTS-8
ADAMTS-15
Procollagen N-proteinases
ADAMTS-2
ADAMTS-3 Process procollagen into mature collagen
ADAMTS-14
GON-ADAMTSs
ADAMTS-9
ADAMTS-20 Potential role in organ morphogenesis
Orphan ADAMTSs
ADAMTS-6
ADAMTS-7
ADAMTS-10 ?
ADAMTS-12
vWFCP ADAMTS-13 von Willebrand cleaving protease
⇤ ADAMTS-16 ?
ADAMTS-18
⇤ ADAMTS-17 ?
ADAMTS-19
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N-proteinase group. They share a high degree of homology among each other (Colige
et al., 2002) and remove the N-terminal propeptide from procollagens, which is a
prerequisite for collagen assembly into mature fibrils (Lee et al., 2012). ADAMTS3,
also known as procollagen II N-peptidase, seems to be the main enzyme that pro-
cesses procollagen II in human cartilage (Fernandes et al., 2001). Mutations in
ADAMTS2 (type I procollagenase) cause Ehlers-Danlos syndrome in humans and
dermatosparaxis in cattle (Colige et al., 1999). Apart from procollagen, no other
substrates have been identified for ADAMTS3 until now .
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2 The aim of the study
VEGF-C is secreted as a 29/31 kDa form (pro-VEGF-C), which needs to be pro-
teolytically processed to remove the N-terminal propeptides in order to release the
active, mature form, which consists largely of the VHD domain. This proteolytic
modification results in a significant increase of its a nity to the angiogenic receptor,
VEGFR-2, and the lymphangiogenic receptor, VEGFR-3. It has been more than a
decade since VEGF-C was discovered, but the knowledge about its proteolytic pro-
cessing is still incomplete. In order to gain more insight into lymphangiogenesis and
in order to design better therapeutic interventions it is paramount to understand
the mechanism(s) of VEGF-C activation. Because of the similar phenotypes of the
Vegfc and Ccbe1 gene deleted mice and the lymphangiogenic potential of CCBE1,
we speculated that CCBE1 and VEGF-C could interact with each other at the level
of proteolytic activation.
The specific aims of the study were:
I. To study the e↵ect of CCBE1 on VEGF-C.
II. To understand the mechanism involved in CCBE1-mediated enhancement of
VEGF-C processing.
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3 Materials and methods
3.1 Clonings
3.1.1 pCHOKE-B-hCCBE1-V5-H6
pCHOKE-B3-hCCBE1-V5-H6 (Michael Jeltsch, maxiprep#1482) and pCHOKE-B-
hCCBE1-V5-H6 (Michael Jeltsch, maxiprep#1462) were digested with SfiI and SphI
(NEB) and dephosphorylated using calf intestinal phosphatase (Finnzymes/Thermo
Scientific). Inserts and vectors were electrophoretically separated on agarose gels
and fragments were visualized under UV light following ethidium bromide staining.
The correct fragments were excised from the gel and purified with the QIAEX II
Gel Extraction Kit (Qiagen). The fragments were ligated using the Rapid Ligation
Kit (Roche). The ligated vector was transformed into NEB 5-alpha chemically
competent cells (NEB). 50µl of each transformation reaction were plated on Luria-
agar plates containing 100µg/ml ampicillin followed by overnight incubation at 37 C.
Clones were picked, inoculated in Luria broth containing 100µg/ml ampicillin and
cultured overnight at 37 C for plasmid isolation using the QIAprep Spin miniprep
kit (Qiagen). The miniprep was sequenced with a ABI 3130xl Genetic Analyzer
(Applied Biosystems) and a DNA maxiprep (Nucleo Bond Xtra Maxi, BIOTOP)
was prepared for the correct clone.
3.1.2 Constructs for ADAMTS proteases
ADAMTS1 (GenBank BC040382) and ADAMTS2 (Genbank BC046456) cDNAs
were received as ready expression vectors (pCMV-SPORT6). ADAMTS14 cDNA
(GenBank BC140263) was received as a gateway entry clone (pENTR223.1) and
transferred into the gateway destination vector (pEF-DEST51) using the LR recom-
binase system (Invitrogen) according to manufacturer’s protocol. ADAMTS3 was
subcloned into pCI-neo (Promega). For this, the insert was derived from pCRII-V5-
H6-hADAMTS3 (Michael Jeltsch, maxiprep #1542) by Blp1 & PmeI digest, and
the vector from pCI-neo (Michael Jeltsch, maxiprep# 1530) by BlpI and SmaI di-
gest. The cloning steps used were similar to the ones used for the preparation of
pCHOKE-B-hCCBE1-V5-H6.
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3.1.3 Constructs for the VEGF-C/VEGF-D chimera
The VEGF-C/VEGF-D chimera version 2 (CDC-V2) construct was created by over-
lapping polymerase chain reaction (PCR) mutagenesis. Two di↵erent PCR products
were obtained; one using 5’-CATGGAGACAGACACACTCCTGCTATG-3’ as the
forward primer and 5’-GATCTCTGTATTATAATGTGCTGCAGCAAATTTTATAG-
TCTCTTC-3’ as the reverse primer, and the other using 5’-GCACATTATAATACAG-
AGATCCTAAAAGTTATAGATGAAGAATGGCA-3’ as the forward primer and 5’-
CCGGATGCTAGCGTTTAAACGAATT-3’ as the reverse primer. For both PCRs
pSec-TagI-CDC-V1 (Michael Jeltsch, maxiprep, #1432) was used as template. Both
PCR products were then used as the template for a second PCR using 5’-CATGGAG-
ACAGACACACTCCTGCTATG-3’ as forward and 5’-CCGGATGCTAGCGTTTA-
AACGAATT-3’ as reverse primer. The final PCR product was inserted into pSec-
TagI-CDC-V1 using BspeI and BsgI as restriction sites.
Other expression clones that were used in this study were: pCHOKE-B-hVEGF-C-
FL-H6 (Michael Jeltsch, maxiprep#1438) and pSecTagI-CDC-V1 (Michael Jeltsch,
maxiprep #1432).
3.2 Antibodies
Anti-VEGF-C antiserum (Baluk et al., 2005), anti-VEGF-C-antibody (R&D Sys-
tems, AF752), anti-VEGF-D antibody (R&D Systems, AF286), anti-V5 antibody
(Invitrogen, #46-0705), anti-ADAMTS3 antibody (Sigma, #A6477), anti-ADAMTS3
antibody (Santa Cruz, sc-21486, #L2303), anti-phosphotyrosine antibody 4G10
(Merck Millipore) and PY20 (BD Transduction Laboratories) were used for both im-
munoprecipitation and Western blotting. Anti-VEGFR-3 antibody (Santa Cruz, sc-
321), chimeric VEGFR-3/IgGFc (Ma¨kinen et al., 2001b) and streptactin sepharose
(IBA) were used for immunoprecipitation. Similarly, streptactin-HRP conjugate
(IBA) and streptavidin-HRP conjugate (R&D Systems, #890803) were used for
Western blots.
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3.3 Cell culture
293T, 293F, PAE-VEGFR-3 (Pajusola et al., 1994), PAE-VEGFR-3/Neuropilin-2
(Ka¨rpanen et al., 2006), Ba/F3-hVEGFR-3/EpoR (Achen et al., 1998), Ba/F3-
mVEGFR-2/EpoR (Achen et al., 2000) and NIH-3T3 cells were grown in D-MEM
(Lonza), PC-3 cells in Ham’s F-12 (Lonza), DU-4475 cells in RPMI 1640 (Lonza),
CHO cells in ↵-MEM (Life Technologies) supplemented with 10% fetal bovine serum
(FBS; Biowest, #1800-500; 20% FBS for DU-4475), 2mM L-glutamine, penicillin
(100U/ml) and streptomycin(100U/ml).
3.4 Stable cell line generation, protein expression and pu-
rification
3.4.1 Stable cell line generation
293F cells were transfected with the mammalian expression plasmid pCI-neo-hADAM-
TS3-V5-H6 and pCHOKE-B-hCCBE1-V5-H6. After 48 hours, the transfected cells
were split to new cell culture dishes at di↵erent dilutions (1:10, 1:20, 1:100, 1:300).
The cells were then selected with G-418 (Roche) at a concentration of 800µg/ml.
Isolated visible colonies were then transferred to new dishes with the help of cloning
rings. The stable expression of CCBE1 and ADAMTS3 was confirmed by Western
blotting.
3.4.2 ADAMTS3 purification
For the purification of his-tagged ADAMTS3, stably transfected cells were grown
in 60 petri dishes and at confluence, the regular medium was replaced by D-MEM
supplemented with 2% FCS, 30µM ZnCl2 and 0.1U heparin/ml. After 5 days, con-
ditioned medium was collected and centrifuged at 13000 rpm for 20 minutes at
4 C. The medium was then dialyzed against phosphate bu↵er using Spectra/Por
dialysis membranes (Spectrum Laboratories. Inc, CA) having a molecular weight
cut o↵ (MWCO) of 15 kDa. The dialysis bu↵er was exchanged every 12 hrs four
times. The pH of the dialyzed medium was adjusted to 8 with 3M Tris/HCl pH
10.5 and the NaCl concentration was adjusted to 450mM followed by addition of
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150 µl Ni2+-NTA-Agarose (Qiagen) slurry per 50 ml of the dialyzed media. Binding
was performed by gentle rotation overnight at 4 C. The Ni2+-NTA resin was rescued
by centrifugation at low speed (500g) for 5 minutes and loaded to a chromatogra-
phy column (Pharmacia Biotech) connected to an A¨kta Explorer FPLC-apparatus
(Pharmacia Biotech/GE Healthcare). The column was washed with 50 column vol-
umes of 3x PBS containing 10% glycerol followed by washes with 10mM and 20mM
imidazole. The elution was performed with 3x PBS containing 10% glycerol and
250mM imidazole. Eluates were collected in 0.5ml fractions. The peak fractions
were dialyzed against 1x TBS and sterilized by filtration using Millex-GV PVDF
Durapore 0.22 µm syringe filter units (Millipore). The proteins were aliquoted and
stored at -70 C.
3.4.3 CCBE1 purification
For the purification of CCBE1, 293T cells stably expressing a strepIII-tagged CCBE1
were grown in 200ml of 10% FBS or D-MEM, 0.2% BSA medium for 6 days.
For the purification of ADAMTS3, the conditioned medium was processed as de-
scribed above except that streptactin sepharose (IBA) was used for binding, 100mM
Tris/HCl pH 8, 150mM NaCl, 1mM EDTA for washing, and washing bu↵er con-
taining 2.5mM desthiobiotin for elution.
3.5 Ba/F3-VEGFR/EpoR assays
The capacity of human VEGF-C to bind to its receptor VEGFR-3 and VEGFR-2 af-
ter processing with CCBE1 and/or ADAMTS3 was analyzed by Ba/F3-VEGFR/EpoR
assays. These assays use murine bone marrow derived Ba/F3 cells expressing
chimeric receptors consisting of the extracellular (EC) ligand binding domain of
VEGFR-2 or VEGFR-3 and the transmembrane and cytoplasmic domain of mouse
erythropoietin receptor (EpoR). Ba/F3 cells require interleukin-3 (IL-3) for their
growth and survival. Ligands of the chimeric receptors are able to eliminate the de-
pendency of Ba/F3-VEGFR/EpoR cells on IL-3, providing a survival signal through
the cytoplasmic domain of the Epo receptor (Blau et al., 1997).
For the assay, Ba/F3 cells were washed twice with PBS and seeded at 20,000
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cells/well to 96-well microtiter plates (Nunc, Thermo Scientific). Conditioned media
of VEGF-C with or without CCBE1 and/or ADAMTS3 were used to supplement
the cell culture media at di↵erent concentrations. After 48hrs, a viability assay
was performed by adding 10µl of 5mg/ml of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (Sigma) in PBS to each well. The plates were incu-
bated for 2 hours at 37 C followed by addition of 100µl of lysis bu↵er (10% SDS,
10mM HCl). The absorbance was measured at 540nm after incubation at 37 C over
night in the dark.
3.6 Cell transfections and metabolic labeling
Cell transfection. Cells were transfected or co-transfected with expression con-
structs using jetPEI transfection reagent (Polypus-transfection Inc) according to the
manufacturer’s recommendations. 24 hrs after transfection, cells were washed twice
with PBS and grown either in D-MEM/0.2 % BSA or in metabolic labeling medium
(see below) for 18 hrs.
Metabolic labeling. Metabolic labeling by incorporating radiolabeled amino acids
cysteine and methionine was used as a sensitive alternative to Western blotting when
immunoprecipitation resulted in non-specific signals from the precipitating anti-
body. The cells were grown in 8µl of Easy Tag Express Protein Labeling Mix (35S,
PerkinElmer) per ml of cysteine/methionine deficient D-MEM medium. The super-
natants were harvested 48hrs after transfection. The harvested supernatants were
centrifuged at high speed for 15 minutes at 4 C and precipitated with the respective
antibodies and protein A sepharose or streptactin for strepIII-tagged proteins. The
binding was performed overnight at 4 C and the samples were separated by PAGE.
The gels were then vacuum-dried for 2 hrs at 80 C and exposed to a phosphoimager
plate or X-ray film. Phosphoimager plates were read on a Typhoon 9400 scanner
(Amersham Biosciences/GE Healthcare).
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3.7 Immunoprecipitation, SDS-PAGE andWestern blotting
Cell supernatants or lysates were precipitated using 50µl of a 50% slurry of protein
A/G Sepharose (PAS/PGS; GE Healthcare) in PBS and gently mixed overnight
at 4 C. The antibody dilutions were used as recommended by the supplier. The
immunoprecipitation reactions were centrifuged at 500g for 4 minutes and washed
three times with ice cold 0.1% Tween-20 in PBS. Then 30µl of reducing 2x Laemmli
standard bu↵er were added to the sepharose and after boiling at 95 C for 5 minutes,
the samples were separated by SDS-PAGE (10% or 4-20% Mini-Protean TGXTM
Gels; Bio-Rad). Membranes and gels were equilibrated in semi-dry Western blot
transfer bu↵er for 15 min. Proteins were then blotted to Protran nitrocellulose
membrane (PerkinElmer) on a Trans-Blot SD Semi-Dry Transfer Cell apparatus
(Bio-Rad) in transfer bu↵er at 37V for 40 min. Membranes were then blocked in
5%BSA-TBS for 1 hr on an orbital shaker at RT. After blocking, the membranes
were incubated with the primary antibody against the indicated proteins at the
indicated dilutions (in 5% BSA-0.1% Tween-TBS) overnight at 4 C with gentle
agitation. The membranes were then washed with 0.1% Tween-TBS at RT followed
by incubation with the appropriate secondary HRP-conjugated antibodies in 10%
skim milk-0.05% Tween-TBS at RT for 1 hr. Membranes were finally washed (0.1%
Tween-TBS for 6 times, 8 mins each wash) and proteins were visualized on an X-ray
film by ECL using Supersignal West Pico maximum sensitivity substrate (Thermo
Scientific). Autoradiographies and Western blots were quantified using the ImageJ
Software (NIH, Bethesda, MD).
3.8 VEGFR-3 phosphorylation
PAE cells expressing VEGFR-3-StrepIII or VEGFR-3/Neuropilin-2 were grown to
confluence and starved overnight in serum free D-MEM.  N C-VEGF-C (Ka¨rpa-
nen et al., 2006), pro-VEGF-C (Veli-Matti Leppa¨nen, unpublished), CCBE1 175
(Veli-Matti Leppa¨nen, unpublished) were diluted to final concentrations of 0.02, 0.4,
5µg/ml in 1ml D-MEM/0.1% BSA and incubated at 37 C for 30 minutes. Cells were
stimulated with the incubated samples for 10 min. After the stimulation, the cells
were lysed in 1% Triton X-100 in 50mM Tris pH 8 or RIPA bu↵er containing 50mM
NaF, 10µg/ml leupeptin, 10µg/ml aprotinin, and 5mM Na3VO4. After lysis, the
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samples were immunoprecipitated with streptactin sepharose, followed by Western
blotting with Anti-phosphotyrosine (pY) antibody 4G10.
Similarly, cells were starved for cross-linking overnight and washed twice with PBS
followed by stimulating the PAE-VEGFR-3-StrepIII and PAE-VEGFR-3/Neuropilin2
cells with  N C-VEGF-C at 100ng/ml, pro-VEGF-C at 1µg/ml and CCBE1 175
at 50µg/ml at 37 C for 3.5 min. Then 5µM DTSSP (Thermo Scientific) in an ice-
cold 5mM sodium citrate (pH 6) was added and the stimulated cells were incubated
for 6.5 min at 37 C. The cells were then washed with ice-cold TBS, lysed with 1%
Triton X-100 in 50mM Tris pH 8 and immunoprecipitated with anti-VEGFR-3 an-
tibodies or pY antibody followed by Western blotting with anti-VEGF-C antibody
or streptavidin-HRP.
3.9 Processing of recombinant pro-VEGF-C with ADAMTS3
2.3µg of pro-VEGF-C (purified from insect cells) was incubated with either 30µg
of ADAMTS3 expressed by insect cells or 8.3µg of ADAMTS3 expressed by 293T
cells. The samples were incubated at 37 C for 12hrs, 24 hrs or 48 hrs. The cleaved
VEGF-C was later analyzed by Western blotting using anti-VEGF-C antiserum.
3.10 Protein mass spectrometry and N-terminal sequencing
Both mass spectrometry of purified CCBE1-StrIII and N-terminal sequencing by
Edman degradation of the ADAMTS3-cleaved VEGF-C were performed by the
Proteomics core unit, Institute of Biotechnology, University of Helsinki. To avoid
overdigestion, ADAMTS3 was titrated to identify the optimal amount of ADAMTS3
required to cleave VEGF-C. The product of activation of 25µg VEGF-C with 60µg
ADAMTS3 in TBS for 24 hours was selected for sequencing.
3.11 Statistical analysis
One-way Anova was used to test for the significance of the Ba/F3 assay results.
Tukey’s test was used as post-hoc test and Graphpad Prism (Graphpad Software,
Inc) was used as analysis software. Error bars represent the standard deviations.
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4 Results
4.1 CCBE1 enhances VEGF-C processing
The CCBE1-coding expression construct, when transfected into 293T cells, resulted
in the appearance of a protein of approx. 50 kDa both in the cellular lysate and
conditioned media. In addition to the 50 kDa form, CCBE1 appeared as a di↵use
band around 100 kDa in the conditioned media (Figure 8 A).
Figure 8: CCBE1 enhances VEGF-C processing. A) Autoradiography showing
CCBE1 at approx. 45-50 kDa in the lysate and the supernatant. The additional
di↵use band of approx. 100 kDa appears only in the supernatant. B) Co-transfection
of the construct coding for CCBE1 increased the processing of pro-VEGF-C into the
mature (21/23 kDa) form of VEGF-C. C) CCBE1 also enhances VEGF-C processing
in trans. Two cell populations individually transfected with constructs coding for
CCBE1 or VEGF-C or their respective conditioned media were mixed and VEGF-C
processing was analyzed.
Three major bands were observed after the transfection of VEGF-C into 293T cells;
unprocessed VEGF-C at 58 kDa, pro-VEGFC at 29/31 kDa and the fully processed
mature form at 21/23 kDa (Figure 8 B, lane 1). When constructs coding CCBE1
and VEGF-C were co-transfected into 293T cells, the majority of the unprocessed
VEGF-C and pro-VEGF-C was converted into mature VEGF-C (Figure 8 B, lane
2). The immunoprecipitation of VEGF-C was performed with VEGFR-3/Fc.
CCBE1 is believed to be a protein of the extracellular matrix. It’s expression appears
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to be non-endothelial and not overlapping with VEGF-C expression (Hogan et al.,
2009). Thus, we looked for the possibility of VEGF-C processing in trans. Two
di↵erent cell populations expressing VEGF-C or CCBE1 were mixed. Similarly, in
another experiment, conditioned media from CCBE1 and VEGF-C expressing cells
were mixed and incubated. In both of these experiments, CCBE1 was found to
enhance VEGF-C processing (Figure 8 C).
4.2 The processed form of VEGF-C activates VEGFR-3 and
VEGFR-2
Figure 9: The processed VEGF-C can activate VEGFR-3 and VEGFR-2.
A) A Ba/F3-hVEGFR-3/EpoR assay showing increased survival in the presence of
conditioned media from cells co-transfected with VEGF-C and CCBE1 coding con-
structs. B) The same as A, but for Ba/F-mVEGFR-2/EpoR cells. ⇤: P-value<0.05,
⇤⇤: P-value<0.01, ⇤⇤⇤: P-value<0.001, ns: no significant.
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In order to verify the function of the processed VEGF-C, a Ba/F3 assay was per-
formed using conditioned media from cells cotransfected with VEGF-C/CCBE1 ex-
pression constructs (Figure 9A and 9B). The survival of Ba/F3-hVEGFR-3/EpoR
cells and Ba/F3-mVEGFR-2/EpoR was significantly increased even with the pro-
VEGF-C compared to the mock. This was probably caused by the VEGF-C pro-
cessing (enhancement) mediated by endogenous CCBE1 or ADAMTS3 produced by
the Ba/F3 cells or as a result of a impure preparation of VEGF-C.
4.3 Processing of VEGF-C by CCBE1 is e cient in 293T
cells
Figure 10: Among all cell lines tested, CCBE1-dependent VEGF-C pro-
cessing is e cient only in 293T cells from all cell lines tested. A) and
B) Autoradiography showing ine cient processing of VEGF-C in CHO, NIH-3T3
and DU-4475 cells compared to processing in 293T cells. Note that DU-4475 do
endogenously express large amounts of CCBE1.
The processing of VEGF-C was analyzed in the cell lines CHO, DU-4475 and NIH-
3T3. DU-4475 endogenously expresses CCBE1 (data not shown). However, there
was no e↵ect on VEGF-C processing by DU-4475 cells or conditioned supernatant
from DU-4475 cells (Figure 10B). Similarly, CHO cells and NIH-3T3 cells were
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co-transfected with expression constructs coding for VEGF-C and CCBE1 and the
processing was less e cient compared to mock- or CCBE1- co-transfected 293T cells
(Figure 10A).
Because CCBE1 is not a protease, it appeared likely that CCBE1 assists in the
cleavage of VEGF-C by a protease that is expressed in 293T cells. To test this
hypothesis, CCBE1 was partially purified from 293T cell supernatant. The mass
spectrometric analysis of the tryptic fragments of CCBE1 revealed ADAMTS3 as
the major protease, that co-purified with CCBE1.
4.4 VEGF-C is processed by ADAMTS3
Figure 11: ADAMTS3 cleaves VEGF-C. A) Autoradiography showing e cient
cleavage of VEGF-C when co-transfected with a construct coding for ADAMTS3.
B) Autoradiography showing no detection of ADAMTS1, -2 and -14 -mediated pro-
cessing of VEGF-C, compared to ADAMTS3 C) Western blot showing cleavage of
VEGF-C by ADAMTS3 purified from insect (S2) cells and mammalian (293T) cells
demonstrating protease activity after purification.
VEGF-C was e ciently processed by ADAMTS3 when co-transfected (Figure 11A).
ADAMTS-2 and -14 belong to the same family of procollagen-N-proteinases (Lee
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et al., 2012) and ADAMTS1 has been implicated in ovarian lymphangiogenesis
(Brown et al., 2006). Therefore, we tested the e↵ect of these proteases on VEGF-C.
However, the co-transfection of constructs coding for ADAMTS1, ADAMTS2 and
ADAMTS14 with VEGF-C didn’t a↵ect the processing of VEGF-C (Figure 11B).
The processing of VEGF-C by ADAMTS3 was further confirmed by incubating the
purified proteins together (Figure 11C). Also in this system, VEGF-C was cleaved
by ADAMTS3.
Interestingly, when constructs coding ADAMTS3 and CCBE1 were co-transfected,
it resulted in cleavage of CCBE1 into a fragment of about 25kDa (Figure 12). The
25kDa size corresponds to the tagged C-terminal collagen-like domain of CCBE1,
which is recognized by streptactin. Also antibodies against ADAMTS3 could pre-
cipitate the 25 kDa fragment of CCBE1.
Figure 12: ADAMTS3 transfection results in CCBE1 cleavage. Western
blot showing CCBE1 cleavage in the presence of ADAMTS3. Note, that the 25kDa
fragment of CCBE1 is precipitated both with streptactin and ADAMTS3 antibodies.
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4.5 CCBE1 enhances ADAMTS3 mediated VEGF-C cleav-
age
ADAMTS3 cleaves VEGF-C. In order to look for a possible cooperation of ADAMTS3
and CCBE1 in VEGF-C processing, the amount of ADAMTS3 and CCBE1 used for
VEGF-C processing were titrated. For titration, conditioned media were mixed in
di↵erent ratios. When CCBE1, VEGF-C and ADAMTS3 were mixed in a ratio of
60:30:1, ADAMTS3 did cleave VEGF-C more e ciently when CCBE1 was present
compared to when CCBE1 was absent (Figure 13A). Additionally, the same con-
ditioned media were used for a Ba/F3-hVEGFR-3/EpoR assay and the results were
consistent with the Western blotting results (Figure 13B).
Figure 13: CCBE1 enhances ADAMTS3-mediated VEGF-C cleavage. A)
Autoradiography showing that the e↵ect of ADAMTS3 and CCBE1 together on
VEGF-C processing is larger than other combinations (VEGF-C, VEGF-C+CCBE1
and VEGF-C+ADAMTS3). The conditioned media from separately transfected
cells were mixed in a ratio of VEGF-C:CCBE1:ADAMTS3=60:30:1. B) Ba/F3-
hVEGFR-3-EpoR assays with the samples from panel A. A significant increase in
cell survival results when VEGF-C-, ADAMTS3- and CCBE1- media are mixed
together compared to VEGF-C-media, VEGF-C-media mixed with CCBE1-media,
or VEGF-C-media mixed with ADAMTS3-media. Note that the increase in sur-
vival of cells after mixing ADAMTS3- and VEGF-C-media was not significant com-
pared to VEGF-C-medium alone. This likely results from the low concentration of
ADAMTS3 (only about 1%) in the mix of conditioned media and the absence of
CCBE1. ⇤: P-value<0.05, ⇤⇤: P-value<0.01, ⇤⇤⇤: P-value<0.001, ns: no significant.
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4.6 Potential activation of VEGF-D by CCBE1
VEGF-D is similar in structure to VEGF-C. This led to the question, whether
VEGF-D also is a substrate for ADAMTS3. No change in the ratio of pro-VEGF-D
and mature VEGF-D was observed, when expression constructs coding for VEGF-D
and CCBE1 were co-transfected (Figure 14A). Both VEGF-C and VEGF-D have a
similar cleavage motif at the beginning of the VEGF homology domain (VHD) after
the N-terminal propeptide. Hence, to study the nature of substrate recognition
by ADAMTS3, two chimeric constructs were made exchanging domains between
VEGF-C and VEGF-D (CDC-V1 and CDC-V2; see Figure 15).
Figure 14: No detection of CCBE1-mediated VEGF-D processing. A) The
autoradiography shows no change in the ratios of the di↵erent VEGF-D forms after
transfection with expression construct coding for CCBE1 compared to mock. B) The
autoradiography shows no significant di↵erences in the processing of VEGF-D, CDC-
V1 and CDC-V2 when transfected with a construct coding for ADAMTS3. VEGF-C
was used as a positive control. Note, that bands higher than 58kDa are detected,
which could represent aggregated protein. C: Anti-VEGF-C (R&D, AF752) and D:
Anti-VEGF-D (R&D, AF286).
No increases of the amount of mature protein were observed when an expression
construct coding for ADAMTS3 was co-transfected. The precipitation of chimeras
from the conditioned media after transfection was done with antibodies against both
VEGF-C and VEGF-D to detect all possible cleavage products. Surprisingly, high
molecular weight bands were seen for all proteins when ADAMTS3 was present
indicating possible ADAMTS3-mediated aggregation (Figure 14B).
N-terminal sequencing of the mature form of recombinant VEGF-C processed by
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Figure 15: Cleavage site comparison between VEGF-C, VEGF-D and
VEGF-C/VEGF-D chimeras
purified ADAMTS3 was performed and the N-terminal sequence was found to be
AHYNT (Figure 15). This N-terminal form of VEGF-C had already been described
(Joukov et al., 1997) and corresponds to the mature form of VEGF-C as produced
by 293EBNA cells.
4.7 The N-terminal domain of CCBE1 enhances the pro-
cessing of pro-VEGF-C into active VEGF-C
ADAMTS3 acts on CCBE1 and probably separates the N-terminal EGF-like and the
C-terminal collagen-like domain. The di culty to produce and purify large amounts
of full-length CCBE1 prompted us to study the ability of the individual CCBE1
domains to aid in the processing of VEGF-C. The phosphorylation of VEGFR-3 in
PAE cells stably expressing human VEGFR-3 was strongly enhanced when applying
pro-VEGF-C together with CCBE1 175 compared to pro-VEGF-C alone (compare
lane 2 and 3, Figure 16A). The strength of phosphorylation was similar to that
obtained from mature VEGF-C (compare lane 1 and 3, Figure 16A).
When VEGFR-3 was precipitated and probed with a VEGF-C antibody, both pro-
and mature VEGF-C were found to be bound to VEGFR-3 (Figure 16B) when
pro-VEGF-C was used together with CCBE1 for the stimulation. In contrast, pro-
VEGF-C alone was only bound to VEGFR-3 in presence of neuropilin-2 (Figure
16D). In order to identify the VEGF-C form bound to the phosphorylated VEGFR-
3, the incubated samples were crosslinked during the phosphorylation step and then
precipitated with phosphotyrosine antibody followed by probing with streptavidin-
HRP (VEGF-C was biotinylated). The cross linking shows that the VEGFR-3
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activation occurs only with the mature VEGF-C (Figure 16C) and pro-VEGF-C
alone is not bound to the phosphorylated VEGFR-3.
Figure 16: The N-terminal domain of CCBE1 regulates VEGF-C me-
diated VEGFR-3 phosphorylation. PAE cells stably expressing VEGFR-3
were stimulated with pro-VEGF-C alone or with the N-terminal domain of CCBE1
(CCBE1 175). A) Strong phosphorylation of VEGFR-3 is seen upon stimulation
with CCBE1 175 and pro-VEGF-C compared to pro-VEGF-C alone. The lower
panel shows the loading control. B) Cross-linking during stimulation shows binding
of pro-VEGF-C and mature VEGF-C to VEGFR-3 when probed with the VEGF-C
antibody. C) On the right is the input of VEGF-C used for the cross-linking exper-
iment. Di↵erences in the migration between lanes 1 and 3 (see Figure 16A to C)
can result from di↵erential N-glycosylation, the presence of the His-tag in  N C-
VEGF-C or di↵erences between cleavage and cDNA truncation. Cross-linking shows
binding of the mature form of VEGF-C to the phosphorylated VEGFR-3. D) PAE
cells stably expressing additionally Nrp2 were used for stimulation and cross linked
as in C. In these cells, pro-VEGF-C is able to bind to VEGFR-3 without the help
of CCBE1 but is not able to induce phosphorylation of VEGFR-3 (Michael Jeltsch,
unpublished data).
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5 Discussion
5.1 CCBE1 regulates VEGF-C processing
VEGF-C has to be proteolytically processed into the mature form that is mainly
composed of the VEGF homology domain (VHD). This processing involves two se-
quential steps: removal of the C-terminal propeptide to give rise to pro-VEGF-C
and finally the removal of the N-terminal propeptide to yield mature VEGF-C.
It is this activation process that governs the di↵erential specificity and a nity of
VEGF-C for VEGFR-3 and VEGFR-2 (Joukov et al., 1997). Hence, understanding
this activation mechanism is important. It is known that the secretory proprotein
convertases furin mediates the C-terminal processing of VEGF-C (Siegfried et al.,
2003). However, the processing of VEGF-C at its N-terminus is not clearly under-
stood and has not been investigated in detail. One of the aims of this study was to
search for the proteins involved in this proteolysis. Studies have shown involvement
of CCBE1, a putative extracellular matrix protein in the regulation of embryonic
lymphangiogenesis (Alders et al., 2009; Hogan et al., 2009). In addition, CCBE1
was shown to have a direct lymphangiogenic potential (Bos et al., 2011). Studies in
mice showed enhanced lymphangiogenic activity of VEGF-C when CCBE1 and pro-
VEGF-C are acting together (Michael Jeltsch, unpublished data). This encouraged
a search for a possible link between VEGF-C and CCBE1.
This study shows that CCBE1 enhances VEGF-C processing when expressed to-
gether. The processed mature VEGF-C could be precipitated both with VEGFR-
3/Fc and VEGFR-2/Fc, confirming that fully processed VEGF-C has both lym-
phangiogenic and angiogenic potential. Also in the Ba/F3 assays, mature VEGF-
C was able to significantly increase the growth and survival of both VEGFR-
2/EpoR and VEGFR-3/EpoR expressing Ba/F3 cells. The processing enhancement
of VEGF-C in the presence of CCBE1 was e cient only in 293T cells. Although
there is a large amount of endogenous CCBE1 secreted by DU-4475 cells, the con-
ditioned media of these cells didn’t influence the processing of VEGF-C. The mass
spectrometry of partially purified CCBE1 showed the presence of ADAMTS3 as its
interacting partner, which was later confirmed by a functional assay. We found
that ADAMTS3 e ciently processes VEGF-C into its active, mature form. Since,
ADAMTS-2 and -14 belong to the same procollagenase family as ADAMTS3 (Lee
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et al., 2012) and ADAMTS1 has a significant role in ovarian lymphangiogenesis
(Brown et al., 2006), they were also tested for their involvement in VEGF-C pro-
cessing. However, no significant processing was detected.
VEGF-D, a structural homolog of VEGF-C, and VEGF-C itself are activated by
plasmin (McColl et al., 2003). VEGF-C and VEGF-D have a similar cleavage mo-
tif at the beginning of the VEGF homology domain (VHD) after the N-terminal
propeptide. Surprisingly, ADAMTS3 and CCBE1 had no e↵ect on VEGF-D pro-
cessing. In a further study using a chimeric form of VEGF-C and VEGF-D, no
e↵ect on processing was detected. The di↵erential substrate recognition of VEGF-
C and VEGF-D by ADAMTS3 might be due to di↵erences between the charge
environments preceding the VHD domain. Nevertheless, further studies need to
be conducted to confirm the cleavage site nature and requirements for ADAMTS3
cleavage.
5.2 The interplay between CCBE1 and ADAMTS3 governs
VEGF-C processing and signaling
Titrations were performed using di↵erent ratios of VEGF-C, CCBE1 and ADAMTS3.
Importantly, ADAMTS3 was e cient at the very low concentration of about 1% pro-
vided CCBE1 was present, and the resulting products could significantly increase
receptor activation. Hence, it is likely that CCBE1 could act as mediator to enhance
VEGF-C processing through ADAMTS3. To confirm the identity of ADAMTS3-
processed VEGF-C, N-terminal sequencing was performed and revealed the presence
of the VHD domain with an N-terminus identical to the one described before (Joukov
et al., 1997).
CCBE1 was di cult to express and purify in large amounts when we used the
full length cDNA. This prevented us from gaining insight into the properties of its
full-length form and behaviour in the cellular context. However, the N-terminal
domain of CCBE1 could be purified and was used for interaction studies in PAE
cells. The phosphorylation of VEGFR-3 was greatly increased when PAE cells were
stimulated with the N-terminal domain of CCBE1 together with pro-VEGF-C in a
short stimulation period. Cross linking during stimulation showed binding of both
pro- and mature form of VEGF-C to VEGFR-3. It has been shown earlier that pro-
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VEGF-C can bind to VEGFR-3 (Joukov et al., 1997; Lee, 1996). In our study, we
show that pro-VEGF-C is bound to VEGFR-3 only in the presence of CCBE1, but
that binding of the mature form of VEGF-C does not require CCBE1. We also show
that mature VEGF-C binds to the phosphorylated receptor and hence is responsible
to mediate VEGFR-3 signaling in the endothelial cells. Interestingly, binding of pro-
VEGF-C to the PAE-VEGFR-3 cells in the absence of CCBE1 was observed only
if the cells expressed additionally neuropilin-2. It is known that pro-VEGF-C binds
to VEGFR-3 in the presence of neuropilin-2 (Ka¨rpanen et al., 2006). ADAMTS3
contains thrombospondin motifs that likely bind to the CD36 receptor present on
endothelial cells (Li et al., 1993). Further, our study shows that ADAMTS3 is
specific for VEGF-C compared to its closest homologues. ADAMTS3 itself is a
complex molecule and possesses multiple domains with di↵erent functions thought
to be involved in cell to cell and cell to matrix interactions. Based on the domain
structure, one could speculate that the receptor binding of ADAMTS3 is important
in addition to its protease function. Additionally, the e cient activity of CCBE1
on VEGF-C on the PAE-VEGFR-3 cell surface compared to the activity of CCBE1
when incubated with VEGF-C in solution reflects the necessity of cellular surface
or extracellular matrix (CCBE1 is thought to be the component of extracellular
matrix) for the localization and concentration of VEGF-C activity in vivo. Our
studies, indicate that ADAMTS3 is also able to regulate CCBE1 itself, but further
functional studies are needed to confirm this aspect of ADAMTS3 function.
Based on this study, we propose a model (Figure 17) by which CCBE1 could
regulate the VEGF-C mediated response to enhance its lymphangiogenic e↵ect.
According to our model, CCBE1 concentrates pro-VEGF-C to VEGFR-3, where
ADAMTS3 or other proteases can cleave VEGF-C into the mature form. This
mature form of VEGF-C has the maximal potential to activate VEGFR-3. Al-
ternatively, ADAMTS3 could cleave VEGF-C without CCBE1 assistance but the
presence of CCBE1 ensures the convergence of VEGF-C towards its receptor or other
structures; hence ensuring its role as a lymphangiogenic factor. This mechanism is
a likely scenario for developmental lymphangiogenesis where VEGF-C and CCBE1
act at the same developmental stage.
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Figure 17: A model for the regulation of VEGF-C activation. Pro-VEGF-
C can bind to VEGFR-3 in the presence of the N-terminal domain of CCBE1.
ADAMTS3 or other unknown proteases process the bound pro-VEGF-C into the
mature form. One half of the dimeric receptor in the complex is drawn transparently
showing that dimerization may or may not be required for the initial binding of pro-
VEGF-C.
6 Future aspects of study
This study shows the mechanism by which CCBE1 may cause the lymphatic phe-
notype of Hennekam syndrome. It also shows that CCBE1 itself is not a stimulator
of lymphangiogenesis but that it regulates VEGF-C function. Plasmin is known to
activate VEGF-C but such activation is most likely important only in pathological
situations, e.g. during wound healing. Therefore, it would be interesting to inves-
tigate the relevance of this mechanism in the context of pathological processes like
cancer. It would also be interesting to study whether cleavage of CCBE1 is required
for its cleavage enhancing activity. This could be accomplished by creating CCBE1
mutants resistant to ADAMTS3 cleavage and then studying the e↵ect of mutant
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CCBE1 on VEGF-C processing and its e↵ect on LECs.
Since CCBE1 was found to modulate lymphangiogenesis, it would be interesting to
validate CCBE1 as a therapeutic target since there is no causal treatment available
to primary lymphedema patients.
7 Conclusion
The aim of this study was to identify the mechanism involved in CCBE1-mediated
lymphangiogenesis. Here we identify ADAMTS3 as a protease that activates VEGF-
C. Moreover, this study implies a model by which CCBE1 can regulate VEGF-C to
enhance its lymphangiogenic e↵ect in vivo. CCBE1 itself has no lymphangiogenic
potential but regulates VEGF-C requiring at least ADAMTS3 protease to exert its
e↵ect.
Lymphatic diseases can be either characterized by deficiency or by enhanced lym-
phangiogenic activity. Hence, there is a need to stimulate lymphangiogenesis in
some diseases and to suppress it in others, and for the development of therapeu-
tic strategies to accomplish these goals. This study provides a model and suggests
CCBE1 as a potential target for lymphangiogenesis modulation.
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